CFO transition
OptimizeRx Corporation CFO transition: Andrew D’Silva to succeed Edward Stelmakh
OptimizeRx Corporation reported in a Form 8-K filed August 12, 2026 that Andrew D’Silva will succeed Edward Stelmakh as Chief Financial Officer, effective January 1, 2027.
In the filing's words
Edward Stelmakh will step down as Chief Financial & Strategy Officer effective December 31, 2026. Mr. Andrew D’Silva will become Chief Financial Officer and Ms. Heather Favazza will become Chief Accounting Officer, each effective January 1, 2027.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | OptimizeRx Corporation (OPRX) |
|---|---|
| Event | Transition |
| Incoming | Andrew D’Silva |
| Outgoing | Edward Stelmakh |
| Title in the filing | Chief Financial Officer |
| Effective | January 1, 2027 |
| 8-K filed | August 12, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | Chief Business Officer, OptimizeRx Corporation |
| SEC CIK | 0001448431 |
OptimizeRx Corporation reported this change in a Form 8-K, Item 5.02, filed August 12, 2026. The filing's own words are quoted above.
Other records naming Edward Stelmakh
1The outgoing officer on this record, matched by name. Career line.
2026-03-12 · 10-K signature
Edward Stelmakh signed OptimizeRx Corp's annual report as Chief Financial & Strategy Officer (principal financial and accounting officer)
Same industry, August 2026
2Other moves filed that month at companies the roster files under SIC “Services-Business Services, NEC”.
3 months ago· 2026-08-14DepartureCREG
Smart Powerr Corp. discloses CFO departure: Yongjiang (Jackie) Shi
3 months ago· 2026-08-03AppointmentRSSS
Research Solutions, Inc. appoints Dave Kutil as CFO
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Andrew D’Silva? Send a correction with the primary source.